Bigfoot Biomedical Stock

bigfootbiomedical.comHealthcareFounded: 2014Funding to Date: $92.5MM

Bigfoot Biomedical is a medical device company developing technologies to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes.

Register for Details

For more details on financing and valuation for Bigfoot Biomedical, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Bigfoot Biomedical.

Register Today

Team

Management Team

Bryan Mazlish
Co-Founder & President
Lane Desborough
Chief Engineer and Co-Founder
Brett Hale
Chief Financial Officer
Ian Hanson
Chief Technology Officer
Jeffrey Brewer
Co-Founder & Chief Executive Officer
Red Maxwell
Chief Marketing Officer
Jyoti Palaniappan
Chief Commercial Officer

Board Members

Robert Kavner
Karen Talmadge Ph.D
Thomas Brener
Quadrant Capital Advisors

Other companies like Bigfoot Biomedical in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

Press Release Bigfoot Biomedical announced today that its innovative Bigfoot Unity™ Diabetes Management Program is now available to diabetes clinics and endocrinology practices in select markets across the U.S. The groundbreaking program reimagines how clinicians...
Press Release Bigfoot Biomedical, a company dedicated to better health outcomes for people with insulin-requiring diabetes, announced today that the FDA has granted 510(k) clearance for first-of-its-kind Bigfoot Unity™ Diabetes Management System, which features connected...
Bigfoot Biomedical, a Milpitas, CA-based company dedicated to health outcomes for people with insulin-requiring diabetes, secured new debt and equity financing of up to $57m from Madryn Asset Management